EDIT

SEC source: 0001179110-20-010969 · edgar.xml · nonDerivative · entry 1

Michaels Lisa Anne · CIK 0001830610 · EVP/Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on November 9, 2021 continuing through November 9, 2024.

SEC source: 0001179110-20-010963 · edgar.xml · nonDerivative · entry 1

Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,907

F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on November 6, 2020. The sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001179110-20-010507 · edgar.xml · nonDerivative · entry 1

Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,135

F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020.

F2 · price: This transaction was executed in multiple trades at prices ranging from $30.88 to $31.77. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001179110-20-009219 · edgar.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,022

F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on August 19, 2020. The sale does not represent a discretionary trade by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $36.44 to $36.66. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001179110-20-009170 · edgar.xml · derivative · entry 3

Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,000

Underlying: Common Stock · 10,000 shares

Expires 2026-09-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise and sale was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020.

F3 · derivative.exercise_date: This option was granted on September 9, 2016 and is scheduled to vest over four years with 25% of the shares having vested on August 22, 2017, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through August 22, 2020.

SEC source: 0001179110-20-009170 · edgar.xml · nonDerivative · entry 2

Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,135

F1 · kind: The exercise and sale was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020.

F2 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.60. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001179110-20-009170 · edgar.xml · nonDerivative · entry 1

Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,135

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise and sale was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020.

SEC source: 0001179110-20-008833 · edgar.xml · nonDerivative · entry 3

Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,135

F2 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on August 6, 2020. The sale does not represent a discretionary trade by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $34.69 to $35.00. The price reported above reflects the weighted average sale price. The Reporting Person herebyundertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001179110-20-008833 · edgar.xml · derivative · entry 4

Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 195,000

Underlying: Common Stock · 10,000 shares

Expires 2026-09-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise and sale was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020.

F4 · derivative.exercise_date: This option was granted on September 9, 2016 and is scheduled to vest over four years with 25% of the shares having vested on August 22, 2017, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through August 22, 2020.

SEC source: 0001179110-20-008833 · edgar.xml · nonDerivative · entry 2

Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,373

F1 · kind: The exercise and sale was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020.

SEC source: 0001179110-20-008833 · edgar.xml · nonDerivative · entry 1

Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,373

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise and sale was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020.

SEC source: 0001179110-20-008367 · edgar.xml · nonDerivative · entry 1

Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,373

F1 · security: The sales reported in this Form 4 were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020.

SEC source: 0001179110-20-007265 · edgar.xml · derivative · entry 1

Vaishnaw Akshay · CIK 0001458494 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,538

Underlying: Common Stock · 11,538 shares

Expires 2030-06-09

F1 · derivative.exercise_date: This option was granted on June 10, 2020 and is scheduled to vest in full on June 10, 2021.

SEC source: 0001179110-20-007280 · edgar.xml · derivative · entry 1

MULLEN JAMES C · CIK 0001226288 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,538

Underlying: Common Stock · 11,538 shares

Expires 2030-06-09

F1 · derivative.exercise_date: This option was granted on June 10, 2020 and is scheduled to vest in full on June 10, 2021.

SEC source: 0001179110-20-007273 · edgar.xml · derivative · entry 1

Hirsch Andrew · CIK 0001586707 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,538

Underlying: Common Stock · 11,538 shares

Expires 2030-06-09

F1 · derivative.exercise_date: This option was granted on June 10, 2020 and is scheduled to vest in full on June 10, 2021.

SEC source: 0001179110-20-007277 · edgar.xml · derivative · entry 1

Hopfield Jessica · CIK 0001648715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,538

Underlying: Common Stock · 11,538 shares

Expires 2030-06-09

F1 · derivative.exercise_date: This option was granted on June 10, 2020 and is scheduled to vest in full on June 10, 2021.

SEC source: 0001179110-20-007263 · edgar.xml · derivative · entry 1

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,538

Underlying: Common Stock · 11,538 shares

Expires 2030-06-09

F1 · derivative.exercise_date: This option was granted on June 10, 2020 and is scheduled to vest on June 10, 2021.

SEC source: 0001179110-20-005605 · edgar.xml · nonDerivative · entry 1

Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,373

F1 · kind: The sales reported in this Form 4 were effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represent the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on May 6, 2020. The sales do not represent a discretionary trade by the Reporting Person.

SEC source: 0001179110-20-001370 · edgar.xml · nonDerivative · entry 2

Albright Charles · CIK 0001682323 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,524

F2 · kind: The sales reported in this Form 4 were effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represent the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on February 6, 2020. The sales do not represent a discretionary trade by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $26.42 to $26.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001179110-20-001362 · edgar.xml · derivative · entry 2

Collins Cynthia · CIK 0001405692 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,750

Underlying: Common Stock · 93,750 shares

Expires 2030-02-05

F2 · derivative.exercise_date: This option was granted on February 6, 2020 and is scheduled to vest over four years in equal monthly installments beginning on March 6, 2020 through February 6, 2024.

SEC source: 0001179110-20-001362 · edgar.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,998

F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on February 6, 2021 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2024.

SEC source: 0001179110-20-001370 · edgar.xml · derivative · entry 3

Albright Charles · CIK 0001682323 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,556

Underlying: Common Stock · 69,556 shares

Expires 2030-02-05

F4 · derivative.exercise_date: This option was granted on February 6, 2020 and is scheduled to vest over four years in equal monthly installments beginning on March 6, 2020 through February 6, 2024.

SEC source: 0001179110-20-001370 · edgar.xml · nonDerivative · entry 1

Albright Charles · CIK 0001682323 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,146

F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on February 6, 2021 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2024.

SEC source: 0001179110-20-001026 · edgar.xml · nonDerivative · entry 2

Albright Charles · CIK 0001682323 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,553

F3 · kind: The sales reported in this Form 4 were effected pursuant to an durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represent the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on January 31, 2020. The sales do not represent a discretionary trade by the Reporting Person.

F2 · balance_after: Such amount includes common stock received by the Reporting Person in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, which is scheduled to vest over four years with 25% of the units vesting on February 6, 2020 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2023, which was previously reported on Table II of a Form 4 filed by the Reporting Person with the SEC on February 8, 2019.

SEC source: 0001179110-20-001026 · edgar.xml · derivative · entry 3

Albright Charles · CIK 0001682323 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,977 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, which vested in full on January 31, 2020.

F4 · derivative.exercise_date: The restricted stock unit award vested in full on January 31, 2020.

F4 · derivative.expiration_date: The restricted stock unit award vested in full on January 31, 2020.

SEC source: 0001179110-20-001026 · edgar.xml · nonDerivative · entry 1

Albright Charles · CIK 0001682323 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,102

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, which vested in full on January 31, 2020.

F2 · balance_after: Such amount includes common stock received by the Reporting Person in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, which is scheduled to vest over four years with 25% of the units vesting on February 6, 2020 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2023, which was previously reported on Table II of a Form 4 filed by the Reporting Person with the SEC on February 8, 2019.

SEC source: 0001179110-20-000468 · edgar.xml · derivative · entry 2

ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2030-01-08

F2 · derivative.exercise_date: This option was granted on January 9, 2020 and is scheduled to vest over four years, with 25% of the shares to vest on January 9, 2021 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through January 9, 2024.

SEC source: 0001179110-20-000468 · edgar.xml · nonDerivative · entry 1

ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on January 9, 2021 continuing through January 9, 2024.

SEC source: 0001179110-19-011289 · edgar.xml · derivative · entry 2

Abrams Judith R · CIK 0001697499 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2029-10-27

F2 · derivative.exercise_date: This option was granted on October 28, 2019 and is scheduled to vest over four years, with 25% of the shares to vest on October 28, 2020 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through October 28, 2023.

SEC source: 0001179110-19-011289 · edgar.xml · nonDerivative · entry 1

Abrams Judith R · CIK 0001697499 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on October 28, 2020 continuing through October 28, 2023.

SEC source: 0001179110-19-010316 · edgar.xml · derivative · entry 3

Collins Cynthia · CIK 0001405692 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2024-08-19

F3 · derivative.exercise_date: This option was granted on September 11, 2019 and is scheduled to vest as to one-third of the shares underlying the option when the closing price of the Issuer's common stock, as reported on the Nasdaq Global Select Market, has for 15 consecutive trading days equaled or exceeded $50.00, $75.00 and $100.00 per share, respectively.

SEC source: 0001179110-19-010316 · edgar.xml · derivative · entry 2

Collins Cynthia · CIK 0001405692 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2029-09-10

F2 · derivative.exercise_date: This option was granted on September 11, 2019 and is scheduled to vest over four years, with 25% of the shares to vest on August 19, 2020 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through August 19, 2023.

SEC source: 0001179110-19-010316 · edgar.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,373

F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over three years in equal yearly installments of one-third of the shares beginning on August 19, 2019 through August 19, 2022.

F1 · shares: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over three years in equal yearly installments of one-third of the shares beginning on August 19, 2019 through August 19, 2022.

SEC source: 0001179110-19-009744 · edgar.xml · nonDerivative · entry 2

Collins Cynthia · CIK 0001405692 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,373

F2 · kind: The sales reported in this Form 4 were effected pursuant to a durable automatic sales instruction letter entered into between the Reporting Person and the issuer in connection with the Reporting Person receiving restricted stock unit awards from the issuer, and represent the sale of shares necessary to meet tax withholding obligations as a result of vesting in restricted stock units on August 19, 2019. The sales do not represent a discretionary trade by the Reporting Person.

SEC source: 0001179110-19-009744 · edgar.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,566

F1 · balance_after: The reported transaction involved the Reporting Peron's receipt of 8,283 shares of common stock on August 19, 2019 in connection with the vesting of a restricted stock unit award. Such amount includes (i) 8,283 shares of common stock received by the Reporting Person on August 19, 2019 that was previously reported on Table II of a Form 4 filed by the Reporting Person with the SEC on February 4, 2019 and (ii) 8,283 shares of common stock received by the Reporting Person in connection with a restricted stock unit award that was previously reported in Table 1 of a Form 4 filed by the Reporting Person with the SEC on August 7, 2019.

SEC source: 0001179110-19-009249 · edgar.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,566

F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest in its entirety on the earlier of (i) the termination of the engagement of the Reporting Person as an interim Chief Executive Officer of Editas Medicine, Inc. and (ii) December 31, 2019.

F1 · price: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest in its entirety on the earlier of (i) the termination of the engagement of the Reporting Person as an interim Chief Executive Officer of Editas Medicine, Inc. and (ii) December 31, 2019.

F2 · balance_after: Such amount includes common stock to be received by the Reporting Person on or about August 19, 2019 in connection with the anticipated vesting of a Restricted Stock Unit award granted to the Reporting Person and previously reported on Table II of a Form 4 filed by the Reporting Person with the SEC on February 4, 2019.

SEC source: 0001179110-19-007675 · edgar.xml · derivative · entry 1

Vaishnaw Akshay · CIK 0001458494 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,538

Underlying: Common Stock · 11,538 shares

Expires 2029-06-11

F1 · derivative.exercise_date: This option was granted on June 12, 2019 and is scheduled to vest in full on June 12, 2020.

SEC source: 0001179110-19-007669 · edgar.xml · derivative · entry 1

Collins Cynthia · CIK 0001405692 · Director · Interim CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,538

Underlying: Common Stock · 11,538 shares

Expires 2029-06-11

F1 · derivative.exercise_date: This option was granted on June 12, 2019 and is scheduled to vest in full on June 12, 2020.

SEC source: 0001179110-19-007680 · edgar.xml · derivative · entry 1

MULLEN JAMES C · CIK 0001226288 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,538

Underlying: Common Stock · 11,538 shares

Expires 2029-06-11

F1 · derivative.exercise_date: This option was granted on June 12, 2019 and is scheduled to vest in full on June 12, 2020.

SEC source: 0001179110-19-007685 · edgar.xml · derivative · entry 1

Hirsch Andrew · CIK 0001586707 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,538

Underlying: Common Stock · 11,538 shares

Expires 2029-06-11

F1 · derivative.exercise_date: This option was granted on June 12, 2019 and is scheduled to vest in full on June 12, 2020.

SEC source: 0001179110-19-007682 · edgar.xml · derivative · entry 1

Hopfield Jessica · CIK 0001648715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,538

Underlying: Common Stock · 11,538 shares

Expires 2029-06-11

F1 · derivative.exercise_date: This option was granted on June 12, 2019 and is scheduled to vest in full on June 12, 2020.

SEC source: 0001179110-19-004095 · edgar.xml · derivative · entry 3

Myer Vickesh · CIK 0001742806 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,307

Underlying: Common Stock · 3,000 shares

Expires 2025-04-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017.

F2 · derivative.exercise_date: This option was granted on April 30, 2015 and is scheduled to vest over four years, with 25% of the shares having vested on April 21, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through April 21, 2019.

SEC source: 0001179110-19-004095 · edgar.xml · nonDerivative · entry 2

Myer Vickesh · CIK 0001742806 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017.

SEC source: 0001179110-19-004095 · edgar.xml · nonDerivative · entry 1

Myer Vickesh · CIK 0001742806 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017.

SEC source: 0001179110-19-003510 · edgar.xml · nonDerivative · entry 1

Hopfield Jessica · CIK 0001648715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,900

SEC source: 0001179110-19-002313 · edgar.xml · derivative · entry 3

Myer Vickesh · CIK 0001742806 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,307

Underlying: Common Stock · 3,000 shares

Expires 2025-04-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017.

F3 · derivative.exercise_date: This option was granted on April 30, 2015 and is scheduled to vest over four years, with 25% of the shares having vested on April 21, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through April 21, 2019.

SEC source: 0001179110-19-002313 · edgar.xml · nonDerivative · entry 2

Myer Vickesh · CIK 0001742806 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017.

F2 · price: This transaction was executed in multiple trades at prices ranging from $20.31 to $20.56. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and the prices at which the transaction was effected.

SEC source: 0001179110-19-002313 · edgar.xml · nonDerivative · entry 1

Myer Vickesh · CIK 0001742806 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017.

SEC source: 0001179110-19-001682 · edgar.xml · derivative · entry 2

Myer Vickesh · CIK 0001742806 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,125

Underlying: Common Stock · 8,125 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of common stock of Editas Medicine, Inc.

F3 · derivative.exercise_date: The restricted stock unit award is scheduled to vest over four years with 25% of the units vesting on February 6, 2020 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2023. Shares will be delivered to the Reporting Person when units vest.

F3 · derivative.expiration_date: The restricted stock unit award is scheduled to vest over four years with 25% of the units vesting on February 6, 2020 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2023. Shares will be delivered to the Reporting Person when units vest.

SEC source: 0001179110-19-001682 · edgar.xml · derivative · entry 1

Myer Vickesh · CIK 0001742806 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,750

Underlying: Common Stock · 48,750 shares

Expires 2029-02-05

F1 · derivative.exercise_date: This option was granted on February 6, 2019 and is scheduled to vest over four years in equal monthly installments beginning on February 6, 2019 through February 6, 2023.